Scantox Transitions Gentronix to Unified Brand After 2024 Acquisition

• Scantox Group announced that Gentronix will now operate under the Scantox brand as Scantox Manchester following full integration.

• The transition combines Gentronix’s genetic toxicology expertise with Scantox’s broader discovery and development platform.

Scantox Group announced that Gentronix, the genetic toxicology contract research organization acquired in 2024, will now operate under the Scantox brand as Scantox Manchester. The move reflects the full integration of Gentronix’s scientific team, capabilities, and client relationships into Scantox’s broader preclinical CRO platform. 

According to the announcement, the transition will not change existing services, personnel, or scientific capabilities. Instead, Gentronix’s expertise will now be delivered through Scantox’s integrated discovery and development offering, expanding access to genetic toxicology and genomic safety services across the organization. 

Since acquiring Gentronix in 2024, Scantox has expanded its genetic toxicology capabilities, including scaling Big Blue® transgenic rodent gene mutation assay capacity, developing an enhanced Ames test program, and acquiring the DuplexSeq™ nonclinical genomic safety business. These investments are intended to strengthen the company’s regulatory toxicology and genomic safety services. 

Scantox operates as an integrated preclinical CRO supporting drug discovery through IND-enabling development, with operations across Denmark, Sweden, Austria, and the United Kingdom. The integration of Gentronix is intended to provide sponsors with coordinated toxicology and safety services within a single development platform. 

“This milestone is built on great science and great people. In eighteen months, the Manchester team has transformed our genetic toxicology and genomic safety offering—without ever losing sight of the scientific rigor and client focus that defined Gentronix.” 

Jeanet Løgsted, Chief Executive Officer of Scantox Group